Intraperitoneal administration of CX546 in Complete Freund’s Adjuvant (CFA)-treated animals relieves mechanical allodynia and reduces immobility during forced swim tests without altering locomotor activities. (A) Intraperitoneal administration of CX546 in CFA-treated animals decreases mechanical allodynia at doses of 25 mg/kg and 12.5 mg/kg, but not at 6.25 mg/kg or 3.125 mg/kg dose. ***P < 0.001, *P < 0.05, two-way ANOVA with post hoc Bonferroni multiple comparison tests. For the 25, 12.5, and 6.25 mg/kg dose, n = 9. For the 3.125 mg/kg dose, n = 6. (B) CFA-treated animals administered with CX546 (25 mg/kg) showed decreased immobility compared with control during the forced swim test. *P < 0.05, unpaired two-tailed Student test. n = 10 for both dimethyl sulfoxide (DMSO) and CX546 groups. (C) Administration of CX546 (25 mg/kg) did not affect locomotor activities of CFA-treated animals. P > 0.05, two-way ANOVA with repeated measures and post hoc Bonferroni multiple comparison tests. n = 7 for both DMSO and CX546 groups. Error bars represent SEM.